Watch for stockholder vote outcome on the escrowed $250K — denial would signal insider confidence issues. The Q1 2027 510(k) submission is the next major catalyst; any delay or FDA feedback could materially impact the stock.
Price Chart
Executive Summary
Conexeu Sciences closed a ~$5M private placement of units (share + warrant) at $3.00/unit, with $250K held in escrow pending stockholder approval. Proceeds will fund working capital and preclinical work ahead of a planned FDA 510(k) submission for Ten Minute Tissue™ in Q1 2027. The financing provides near-term cash runway but dilutes existing holders by ~1.67M shares plus warrants, and the stockholder-approval condition introduces execution risk.
Key Financial Metrics
Key Facts
- Closed private placement of ~$5M via 1,666,667 units at $3.00/unit, each unit = 1 share + 1 warrant (exercise $3.00, 24-month term).
- $250,000 of subscriptions from management/directors held in escrow pending stockholder approval under Nasdaq Rule 5635(c).
- Proceeds for working capital, manufacturing scale-up, regulatory testing, and preclinical work ahead of planned FDA 510(k) submission in Q1 2027.
- No placement agent or commissions; led by existing shareholders including CEO Miles Harrison and CCO David Bogart.
- Company remains on track for 510(k) submission in Q1 2027 after Oct. 6 update confirming scaled-up batches met specifications.
Financial Impact
~$5M gross proceeds; dilution of ~1.67M shares (plus warrants) against an undisclosed current share count; $250K contingent on stockholder vote.
Risk Factors
- Stockholder approval may not be obtained, preventing release of $250K and signaling lack of insider confidence.
- Dilution from 1.67M shares plus warrants could pressure the stock if not absorbed by the market.
- Preclinical-stage company with no approved products; 510(k) submission timeline and FDA clearance are uncertain.
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3382156 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | 8-K | $3.33 $3.30 | ▲ +0.90% | ▼ −0.28% | $2.94 (+11.71%) |
Oct 15, 2026 11d ago | Press Release | $3.06 $3.29 | ▲ +7.52% | ▲ +7.09% | $2.94 (−3.92%) |
Oct 6, 2026 20d ago | Press Release | $3.66 $3.64 | ▼ −0.55% | ▼ −0.31% | $2.94 (−19.67%) |
Jun 29, 2026 17w ago | 3 | $10.24 $10.92 | ▲ +6.64% | ▲ +5.86% | $2.94 (−71.29%) |
Jun 23, 2026 17w ago | Insider Buy | $10.69 $10.22 | ▼ −4.40% | ▼ −4.54% | $2.94 (−72.50%) |
Jun 3, 2026 20w ago | Press Release | $16.85 $16.00 | ▼ −5.04% | ▼ −5.44% | $2.94 (−82.55%) |
May 14, 2026 23w ago | Insider Cluster | — | awaiting T+1 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers